Onc Now | Episode 29
In this episode of Onc Now, Jonathan Sackier is joined by Arndt Vogel, a Professor and Clinician Scientist in the Division of Gastroenterology and Hepatology at the University of Toronto, Canada. Their conversation centres around the latest advances in hepatocellular carcinoma, the promise of immunotherapy, and how emerging biomarkers are reshaping treatment decisions for patients with liver cancer.
Apple | Spotify | Amazon Music | Youtube (25 mins)
Speaker bio:
Arndt Vogel is an internationally recognised expert in gastrointestinal oncology, with a particular focus on hepatocellular carcinoma and other liver malignancies. He serves as a Professor of Medicine and Clinician Scientist at the University of Toronto, where he leads research aimed at integrating molecular insights into clinical practice.
Timestamps:
00:00 – Introduction
01:00 – Origin of interest in oncology
02:22 – Biggest breakthroughs
04:40 – ESMO highlights
06:30 – Importance of clinical guidelines
09:15 – Research highlights in hepatocellular carcinoma
12:30 – Immunotherapy advances
15:50 – Emerging biomarkers in hepatocellular carcinoma
19:19 – Key unmet needs for patients
23:40 – Three magic wishes for healthcare
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.
